September 12, 2017
Berkeley Lovelace Jr.
A Johnson & Johnson pharmaceutical unit focused on the development of hepatitis C research said it will end its program amid a crowded market.
Janssen Sciences Ireland cited the increasing availability of a number of highly effective therapies addressing the medical need.
Shares of biotech company Achillion Pharmaceuticals were more...
BOARD OF ADVISORS
NEWS & UPDATES